ATE65798T1 - Menschlicher granuloxcyt-koloniestimulierungsfaktor. - Google Patents

Menschlicher granuloxcyt-koloniestimulierungsfaktor.

Info

Publication number
ATE65798T1
ATE65798T1 AT86901138T AT86901138T ATE65798T1 AT E65798 T1 ATE65798 T1 AT E65798T1 AT 86901138 T AT86901138 T AT 86901138T AT 86901138 T AT86901138 T AT 86901138T AT E65798 T1 ATE65798 T1 AT E65798T1
Authority
AT
Austria
Prior art keywords
human
granuloxcyte
stimulation factor
colony stimulation
csf
Prior art date
Application number
AT86901138T
Other languages
English (en)
Inventor
Masayoshi Ono
Hitoshi Nomura
Masahiko Tamura
Masahiko Matsumoto
Tatsumi Yamazaki
Osami Yamamoto
Yuichi Hirata
Yasuo Sekimori
Masayuki Tsuchiya
Shigekazu Nagata
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP60023777A external-priority patent/JPH0615477B2/ja
Priority claimed from JP60269455A external-priority patent/JPS62129298A/ja
Priority claimed from JP60270838A external-priority patent/JPH06102021B2/ja
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE65798T1 publication Critical patent/ATE65798T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT86901138T 1985-02-08 1986-02-07 Menschlicher granuloxcyt-koloniestimulierungsfaktor. ATE65798T1 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
JP60023777A JPH0615477B2 (ja) 1985-02-08 1985-02-08 感染防禦剤
JP20606685 1985-09-17
JP20963885 1985-09-20
JP26945685 1985-12-02
JP60269455A JPS62129298A (ja) 1985-12-02 1985-12-02 新規ポリペプチド
JP27083985 1985-12-03
JP60270838A JPH06102021B2 (ja) 1985-12-03 1985-12-03 新規なポリペプチド
PCT/JP1986/000052 WO1986004605A1 (fr) 1985-02-08 1986-02-07 Facteur de stimulation de colonies de granulocytes humains
EP86901138A EP0215126B1 (de) 1985-02-08 1986-02-07 Menschlicher granuloxcyt-kolonie-stimulierungsfaktor

Publications (1)

Publication Number Publication Date
ATE65798T1 true ATE65798T1 (de) 1991-08-15

Family

ID=27564006

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86901138T ATE65798T1 (de) 1985-02-08 1986-02-07 Menschlicher granuloxcyt-koloniestimulierungsfaktor.

Country Status (6)

Country Link
EP (1) EP0215126B1 (de)
AT (1) ATE65798T1 (de)
BG (1) BG61925B2 (de)
DE (1) DE3680613D1 (de)
HK (1) HK66293A (de)
WO (1) WO1986004605A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
EP0396158A1 (de) * 1985-08-23 1990-11-07 Kirin-Amgen, Inc. Herstellung des die pluripotente Granulozyt-Kolonie stimulierenden Faktors
US6004548A (en) * 1985-08-23 1999-12-21 Amgen, Inc. Analogs of pluripotent granulocyte colony-stimulating factor
DE3681551D1 (de) * 1985-09-30 1991-10-24 Chugai Pharmaceutical Co Ltd Menschlicher granulozyten-colony stimulierender faktor.
JPH0618778B2 (ja) * 1985-10-04 1994-03-16 中外製薬株式会社 白血球減少症治療剤
DE3777845D1 (de) * 1986-01-22 1992-05-07 Chugai Pharmaceutical Co Ltd Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.
ATE65403T1 (de) * 1986-01-22 1991-08-15 Chugai Pharmaceutical Co Ltd Pharmazeutischer stoff fuer die foerderung der wiederherstellung der haematopoietischen faehigkeit.
DK203187A (da) * 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
JPH01500483A (ja) * 1986-08-11 1989-02-23 シタス　コーポレイション Ｇ‐ｃｓｆ及びそのミューテインの発現
JP2583770B2 (ja) * 1986-09-17 1997-02-19 大塚製薬株式会社 遺伝子
JPH0725689B2 (ja) * 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
NO176799C (no) * 1986-12-23 1995-05-31 Kyowa Hakko Kogyo Kk DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid
US5214132A (en) * 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5194592A (en) * 1986-12-23 1993-03-16 Kyowa Hakko Kogyo Co. Ltd. Monoclonal antibodies to novel polypeptide derivatives of human granulocyte colony stimulating factor
KR930007430B1 (ko) * 1987-07-16 1993-08-10 쉐링 코포레이션 크로마토그래피 단계에 의한 과립구-대식세포 콜로니-자극 인자의 정제방법
US5391706A (en) * 1987-07-16 1995-02-21 Schering Plough Corporation Purification of GM-CSF
GB2213821B (en) * 1987-12-23 1992-01-02 British Bio Technology Synthetic human granulocyte colony stimulating factor gene
CA2006596C (en) * 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US6166183A (en) * 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
EP0648501A1 (de) * 1989-10-10 1995-04-19 Amgen Inc. Zusammensetzungen, die G-CSF enthalten zur Behandlung der Vorbeugung von Infektionen bei Hunden und Katzen Tieren
NZ236819A (en) * 1990-02-03 1993-07-27 Max Planck Gesellschaft Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
US5505944A (en) * 1992-09-09 1996-04-09 Nippon Kayaku Kabushiki Kaisha Physiologically active substance NK175203, process for production thereof and pharmaceutical use thereof
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
BR0211071A (pt) 2001-07-11 2004-12-21 Maxygen Holdings Ltd Conjugado polipeptìdico apresentando atividade de g-csf, método para preparar um conjugado de g-csf, composição, método para tratar um mamìfero sofrendo de um nìvel neutrofìlico insuficiente, e, uso do conjugado polipeptìdico
SI21102A (sl) 2001-12-19 2003-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika
ES2403932T3 (es) 2002-08-27 2013-05-22 Biokine Therapeutics Ltd. Antagonista de CXCR4 y uso del mismo
JP5137821B2 (ja) 2005-06-01 2013-02-06 マキシジェン， インコーポレイテッド Ｐｅｇ化されたｇ−ｃｓｆポリペプチドおよびその製造方法
US8663651B2 (en) 2006-12-21 2014-03-04 Biokine Therapeutics Ltd. T-140 peptide analogs having CXCR4 super-agonist activity for immunomodulation
PE20110426A1 (es) 2008-07-23 2011-07-01 Ambrx Inc Polipeptidos g-csf bovinos modificados
BRPI0920841A2 (pt) 2008-10-02 2021-01-26 Octapharma Biopharmaceuticals Gmbh precursor de g-csf humana recombinante, polinucleotídeo, vetor, célula transfectada e método para expressar g-csf
WO2010092571A2 (en) 2009-02-11 2010-08-19 Yeda Research And Development Co. Ltd. Short beta-defensin-derived peptides
US9427456B2 (en) 2009-06-14 2016-08-30 Biokine Therapeutics Ltd. Peptide therapy for increasing platelet levels
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
US9439942B2 (en) 2012-04-24 2016-09-13 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
AU2016291817A1 (en) 2015-07-16 2018-02-22 Biolinerx Ltd. Compositions and methods for treating cancer
BR112018016924A2 (pt) 2016-02-23 2019-01-02 Biolinerx Ltd método de seleção de regime de tratamento para indivíduo que tem leucemia mieloide aguda (lma), método de maximização de resposta ao tratamento de leucemia mieloide aguda (lma), método de tratamento de lma, antagonista de cxcr4 e agente quimioterápico no tratamento de lma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54140789A (en) * 1978-04-22 1979-11-01 Jitsuken Doubutsu Chuo Kenkiyu Culturing of colony stimulating factor producing tumor cell
JPS6030654B2 (ja) * 1980-12-31 1985-07-17 株式会社林原生物化学研究所 ヒトコロニ−刺激因子の製造方法
JPS5978122A (ja) * 1982-10-27 1984-05-04 Ajinomoto Co Inc コロニ−刺激因子の製造法
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor

Also Published As

Publication number Publication date
DE3680613D1 (de) 1991-09-05
EP0215126A1 (de) 1987-03-25
BG61925B2 (bg) 1998-09-30
WO1986004605A1 (fr) 1986-08-14
EP0215126A4 (de) 1987-10-05
EP0215126B1 (de) 1991-07-31
HK66293A (en) 1993-07-16

Similar Documents

Publication Publication Date Title
DE3680613D1 (de) Menschlicher granuloxcyt-kolonie-stimulierungsfaktor.
MY101972A (en) Primate interleukin - 4
ATE67517T1 (de) Menschlicher granulozyten-colony stimulierender faktor.
AU596997B2 (en) Pharmaceutical composition for the treatment of leukopenia
ES8307297A1 (es) Proceso para la produccion microbiana de interferon fibro- blasto humano
MD430C2 (ro) Procedeu de obţinere a interferonelor leucocitare umane
MY102546A (en) Human immune interferon
EP0228018A3 (en) Gm-csf protein, its derivatives, preparation of such proteins and their use
ES8205431A1 (es) Procedimiento para la preparacion de un plasmido que codifica para la secuencia de aminoacidos del interferon de leuco- citos humanos.
AU7177896A (en) Multidrug resistance gene
EP0088622A3 (en) Animal interferons, processes involved in their production, compositions containing them, dna sequences coding therefor and expression vehicles containing such sequences and cells transformed thereby
NZ505063A (en) Pharmaceutical use of long pentraxin PTX3 in treating tumour conditions
EP0231819A3 (en) Pharmaceutical agent for the treatment of myelogenous leukemia
EP0835661A3 (de) Menslisches Interferon-Beta 2A zur Verwendung als Arzneimittel
JPS6485098A (en) Glycoprotein and production thereof
MY103542A (en) Expression vectors for the production of human granulocyte macrophage colony stimulating factor in a mammalian cell host
ATE88216T1 (de) Erhoehung der expression von genen in mikroorganismen.
AU2430588A (en) Mutant acidic fibroblast growth factor
SE8605459L (sv) Ny celltillvextreglerande faktor
DE3853590D1 (de) Rinder granulocyt-makrophagenkolonie stimulierender faktor.
AU6560886A (en) DNA sequence containing the DNA sequence coding for human tissue plasminogen activator originating from human normal cells, recombinant DNA incorporating the DNA sequence, host cells transformed with the recombinant DNA, and process for producing human tissue plasminogen activator by use of the host cells
JPS6485095A (en) Novel physiologically active polypeptide
JPS6485094A (en) Novel physiologically active polypeptide

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time